pocketful logo
Beryl Drugs Ltd logo

Beryl Drugs Ltd

NSE: BSE: 524606

₹20.19

(-7.17%)

Sat, 07 Mar 2026, 05:18 am

mtf coin illustrationMTF 5x

Beryl Drugs Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    10.12

  • Net Profit

    0.58

  • P/B

    1.13

  • Sector P/E

    40.52

  • P/E

    18.46

  • EV/EBITDA

    5.24

  • Debt/Equity (Industry)

    0.23

  • Interest Cover (Industry)

    10.03

  • ROCE (Industry)

    12.82

  • RONW (Industry)

    12.23

  • ROE

    6.30

  • ROCE

    9.93

  • Debt/Equity

    0.50

  • EPS (TTM)

    0.03

  • Dividend Yield

    0

  • Book Value

    18.63

  • Interest Cover

    2.61

Analysis

all

thumbs up icon

Pros

  • Beryl Drugs is profitable, therefore cash runway is not a concern.
  • Beryl Drugs is profitable, therefore cash runway is not a concern.
  • Debt is well covered by operating cash flow (95.6%, greater than 20% of total debt).
  • Debt is covered by short term assets, assets are 1.5x debt.
  • Beryl Drugs's cash and other short term assets cover its long term commitments.
thumbs up icon

Cons

  • Unable to evaluate Beryl Drugs's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Beryl Drugs's dividend against the top 25% market benchmark as the company has not reported any payouts.
  • Beryl Drugs's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • The level of debt compared to net worth has increased over the past 5 years (25.7% vs 47% today).
  • Beryl Drugs's level of debt (47%) compared to net worth is high (greater than 40%).

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters26.3826.3826.3826.3826.38
FII00000
DII00000
Public73.6273.6273.6273.6273.62
Government00000

Read More

Technical Analysis

RSI

45.03

MACD

-0.63

50 DMA

22.00

200 DMA

21.93

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic27.8124.3622.2820.9118.8317.4614.01
Fibonacci24.3623.0522.2320.9119.6018.7817.46
Camarilla21.1420.8220.5120.9119.8719.5619.24

Pivots Level: Classic

R3

+6.90

27.81

R2

+3.45

24.36

R1

+1.36

22.28

20.91
20.91
Pivot Point
LTP: 19.96

S1

-2.09

18.83

S2

-3.45

17.46

S3

-6.90

14.01

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    20.39

  • 20-EMA

    20.94

  • 30-EMA

    21.28

  • 50-EMA

    21.69

  • 100-EMA

    22.16

  • 200-EMA

    23.11

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
09 Feb 2026egm
09 Feb 2026board-meetingsQuarterly Results, EGM
13 Nov 2025board-meetingsQuarterly Results
02 Sept 2025agm
09 Sept 2024agm
25 Aug 2023agm
02 Sept 2022agm
03 Sept 2021agm

Read More

Peer Comparison

Beryl Drugs Ltd logo

Beryl Drugs Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Lupin Ltd logo

Lupin Ltd

Read More

Beryl Drugs Ltd About

Beryl Drugs is principally engaged in manufacturing of bulk drugs

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1993

Headquarters

CEO

Sudhir Sethi

Employees

Contact

Website icon

Website

http://www.beryldrugs.com

Email icon

Email

beryldrugs25@yahoo.com

Phone icon

Phone

91-731-25076375/3046366

Location icon

Location

133 Kanchan Bag, , Indore, Madhya Pradesh, 452001

Read More

Beryl Drugs Ltd Company History

YearHistory
1994
  • The company was incorporated as a medicine pharmaceutical manufacturer.
2007
  • The board of directors decided to issue 1.50 million equity shares and 2 million warrants to promoters and strategic investors on a preferential basis.
  • The authorized share capital was increased from Rs 5.50 crores to Rs 10.00 crores.
2008
  • The board of directors approved the issue of 35 lacs warrants to promoters and strategic investors on a preferential basis.
2015
  • Beryl Drugs and MPPHSCL signed a deal worth Rs 11.8 crores.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
PRADEEP KUMAR JAINBuy10000022.516 Dec 2025
SAMIR NARENDRA GUPTASell9992122.516 Dec 2025
NARENDRAKUMAR BHAGWANDAS GUPTASell10000024.8528 Feb 2025
SAMIR NARENDRA GUPTABuy10000124.8528 Feb 2025
NARENDRAKUMAR BHAGWANDAS GUPTASell3803843.2309 Sept 2024
NARENDRAKUMAR BHAGWANDAS GUPTASell7447538.606 Sept 2024
KRUNALKUMAR KANUJI THAKORBuy2389341.5710 Jun 2024
KRUNALKUMAR KANUJI THAKORSell3698041.4710 Jun 2024
SAMIR NARENDRA GUPTABuy9100728.7801 Apr 2024
HINDON TRADERS & BROKERS PRIVATE LIMITEDSell8500028.5201 Apr 2024

Read More

Beryl Drugs Ltd News

Beryl Drugs Reports Q3 FY26 Loss of ₹16.77 Lacs

Beryl Drugs Limited posted a net loss of ₹16.77 lacs in Q3 FY26 compared to profit of ₹5.22 lacs in Q3 FY25. Revenue declined 28.87% YoY to ₹377.68 lacs amid manufacturing facility suspension.

09 Feb 2026

co actions results

Beryl Drugs Files Q3FY26 Compliance Under Regulation 57(5)

Beryl Drugs Limited submits compliance filing to BSE stating non-applicability of Regulation 57(5) for Q3FY26 as company has no non-convertible securities requiring interest or dividend payments during the quarter.

06 Jan 2026

stocks

Beryl Drugs Board Approves Key Appointments & Transactions

Beryl Drugs Limited's board meeting on January 3, 2026, approved director appointments including Mr. Shailendra Pathak as Whole Time Director and Mrs. Neha Sarda as Independent Director, subject to shareholder approval.

03 Jan 2026

stocks

Beryl Drugs Limited and Beryl Securities Limited Publish Quarterly Financial Results

Beryl Drugs Limited and Beryl Securities Limited published their unaudited financial results for the quarter ended September 30, 2025, in newspapers including Free Press (English) and Choutha Sansar (Hindi) editions. The companies fulfilled their regulatory disclosure requirements under SEBI listing obligations by making their quarterly financial performance publicly available.

15 Nov 2025

earnings

Beryl Drugs Reports Net Profit of Rs 2.11 Lakhs in Q1 Despite Manufacturing Facility Suspension

Beryl Drugs Limited reported net profit of Rs 2.11 lakhs for the quarter ended June 30, 2025, compared to a net loss of Rs 36.79 lakhs in the corresponding quarter of the previous year. Revenue from operations declined to Rs 483.58 lakhs from Rs 287.3 lakhs in the previous quarter. The company's manufacturing facility is partially under suspension and upgradation, which has impacted turnover for the entire quarter. Total expenses decreased to Rs 476.61 lakhs. Basic and diluted earnings per share stood at Rs 0.04. The Board of Directors approved these unaudited financial results in their meeting held on August 7, 2025.

07 Aug 2025

earnings

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800